宁波美诺华药业股份有限公司第五届董事会第二十四次会议决议公告

Group 1 - The company held its 24th meeting of the fifth board of directors on February 2, 2026, to discuss urgent matters, with all five directors present and in compliance with relevant laws and regulations [2][3][4] - The board approved a proposal to lower the conversion price of the "Meinuo Convertible Bonds" from 25.68 yuan per share to 21.28 yuan per share, effective from February 4, 2026 [3][11][18] Group 2 - The "Meinuo Convertible Bonds" will be suspended from conversion on February 3, 2026, and will resume on February 4, 2026 [8][11] - The company issued 520 million yuan worth of convertible bonds in January 2021, with an initial conversion price of 37.47 yuan per share [8][11] - The conversion price has been adjusted multiple times since issuance, with the most recent adjustment being from 25.68 yuan to 21.28 yuan due to stock price performance [9][10][15][18] Group 3 - The adjustment to the conversion price was triggered by the stock price being below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [15][16] - The board's decision to lower the conversion price was aimed at supporting the company's long-term development and optimizing its capital structure [16][18]